Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.02
-0.02-1.92%
At close: -
$1.02
0.000.00%
After Hours: May 23, 4:01 PM EDT
Comments
Loading...
Zura Bio Analyst Ratings and Price Targets | NASDAQ:ZURA | Benzinga
Zura Bio Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Zura Bio Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Guggenheim
Chardan Capital
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Zura Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | — | Oppenheimer | Jeff Jones34% | $19 → $17 | Maintains | Outperform | Get Alert |
| 04/03/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor44% | $5 → $3 | Maintains | Neutral | Get Alert |
| 03/26/2025 | Buy Now | — | Oppenheimer | Jeff Jones34% | $20 → $19 | Maintains | Outperform | Get Alert |
| 03/26/2025 | Buy Now | — | Guggenheim | Yatin Suneja51% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2025 | Buy Now | — | Chardan Capital | Matthew Barcus53% | $12 → $10 | Maintains | Buy | Get Alert |
| 12/24/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor44% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 12/11/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | — | Reiterates | Overweight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor44% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 11/11/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor44% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 11/08/2024 | Buy Now | — | Chardan Capital | Matthew Barcus53% | $14 → $12 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | — | Leerink Partners | Faisal Khurshid31% | → $15 | Initiates | → Outperform | Get Alert |
| 10/21/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor44% | $5 → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 10/18/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | — | Reiterates | → Overweight | Get Alert |
| 09/19/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi54% | $26 → $26 | Maintains | Overweight | Get Alert |
| 09/05/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor44% | → $5 | Initiates | → Neutral | Get Alert |
| 08/15/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | — | Reiterates | → Overweight | Get Alert |
| 06/17/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | — | Reiterates | → Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer52% | — | Initiates | → Overweight | Get Alert |
| 05/10/2024 | Buy Now | — | Oppenheimer | Jeff Jones34% | $16 → $21 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi54% | → $26 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | — | Oppenheimer | Jeff Jones34% | $17 → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 10/10/2023 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov33% | → $10 | Initiates | → Buy | Get Alert |
| 08/25/2023 | Buy Now | — | Oppenheimer | Justin Kim36% | → $17 | Initiates | → Outperform | Get Alert |
| 08/15/2023 | Buy Now | — | Raymond James | Steven Seedhouse58% | $20 → $22 | Maintains | Strong Buy | Get Alert |
| 06/22/2023 | Buy Now | — | Guggenheim | Yatin Suneja51% | → $20 | Initiates | → Buy | Get Alert |
| 06/14/2023 | Buy Now | — | Chardan Capital | Matthew Barcus53% | → $14 | Initiates | → Buy | Get Alert |
| 05/24/2023 | Buy Now | — | Raymond James | Steven Seedhouse58% | → $20 | Initiates | → Strong Buy | Get Alert |
FAQ
What is the target price for Zura Bio (ZURA) stock?
The latest price target for Zura Bio (NASDAQ:ZURA) was reported by Oppenheimer on May 9, 2025. The analyst firm set a price target for $17.00 expecting ZURA to rise to within 12 months (a possible 1566.67% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zura Bio (ZURA)?
The latest analyst rating for Zura Bio (NASDAQ:ZURA) was provided by Oppenheimer, and Zura Bio maintained their outperform rating.
When was the last upgrade for Zura Bio (ZURA)?
There is no last upgrade for Zura Bio
When was the last downgrade for Zura Bio (ZURA)?
There is no last downgrade for Zura Bio.
When is the next analyst rating going to be posted or updated for Zura Bio (ZURA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zura Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zura Bio was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating Zura Bio (ZURA) correct?
While ratings are subjective and will change, the latest Zura Bio (ZURA) rating was a maintained with a price target of $19.00 to $17.00. The current price Zura Bio (ZURA) is trading at is $1.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
